Sinopharm Group Valuation
| X2S Stock | EUR 2.58 0.00 0.00% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Sinopharm Group has a current Real Value of €2.15 per share. The regular price of the company is €2.58. Our model measures the value of Sinopharm Group from inspecting the company fundamentals such as Total Debt of 8.42 B, current valuation of 15.96 B, and Net Asset of 335.41 B as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Sinopharm Group's price fluctuation is slightly risky at this time. Calculation of the real value of Sinopharm Group is based on 3 months time horizon. Increasing Sinopharm Group's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Sinopharm Group's intrinsic value may or may not be the same as its current market price of 2.58, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.58 | Real 2.15 | Hype 2.58 |
The intrinsic value of Sinopharm Group's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sinopharm Group's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sinopharm Group Co helps investors to forecast how Sinopharm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sinopharm Group more accurately as focusing exclusively on Sinopharm Group's fundamentals will not take into account other important factors: Sinopharm Group Total Value Analysis
Sinopharm Group Co is at this time projected to have takeover price of 15.96 B with market capitalization of 15.96 B, debt of 8.42 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sinopharm Group fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
15.96 B | 15.96 B | 8.42 B |
Sinopharm Group Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The newest return on assets of Sinopharm implies not a very effective usage of assets in January.About Sinopharm Group Valuation
The stock valuation mechanism determines Sinopharm Group's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Sinopharm Group based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Sinopharm Group. We calculate exposure to Sinopharm Group's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sinopharm Group's related companies.8 Steps to conduct Sinopharm Group's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Sinopharm Group's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Sinopharm Group's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Sinopharm Group's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Sinopharm Group's revenue streams: Identify Sinopharm Group's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Sinopharm Group's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Sinopharm Group's growth potential: Evaluate Sinopharm Group's management, business model, and growth potential.
- Determine Sinopharm Group's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Sinopharm Group's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Sinopharm Stock Analysis
When running Sinopharm Group's price analysis, check to measure Sinopharm Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinopharm Group is operating at the current time. Most of Sinopharm Group's value examination focuses on studying past and present price action to predict the probability of Sinopharm Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinopharm Group's price. Additionally, you may evaluate how the addition of Sinopharm Group to your portfolios can decrease your overall portfolio volatility.